RNAZ

Transcode Therapeutics Inc

RNAZ, USA

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

https://www.transcodetherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RNAZ
stock
RNAZ

TransCode Announces Collaboration for Phase 2a Trial TipRanks

Read more →
RNAZ
stock
RNAZ

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.34 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.09 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.67

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 11.31% of the total shares of Transcode Therapeutics Inc

1.

Anson Funds Management LP

(6.2635%)

since

2025/03/31

2.

Goldman Sachs Group Inc

(3.3636%)

since

2025/06/30

3.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7851%)

since

2025/07/31

4.

Fidelity Series Total Market Index

(0.2167%)

since

2025/07/31

5.

Fidelity Extended Market Index

(0.1799%)

since

2025/07/31

6.

UBS Group AG

(0.1718%)

since

2025/06/30

7.

Spartan Extended Market Index Pool F

(0.1408%)

since

2025/07/31

8.

Spartan Total Market Index Pool G

(0.0599%)

since

2025/07/31

9.

SouthState Bank Corp

(0.0578%)

since

2025/06/30

10.

Tower Research Capital LLC

(0.0482%)

since

2025/06/30

11.

NT Ext Equity Mkt Idx Fd - L

(0.0071%)

since

2025/06/30

12.

Northern Trust Extended Eq Market Idx

(0.0071%)

since

2025/06/30

13.

Fidelity Total Market Index

(0.005%)

since

2025/07/31

14.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.002%)

since

2025/06/30

15.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0017%)

since

2024/12/31

16.

SBI Securities Co Ltd

(0.0012%)

since

2025/06/30

17.

Royal Bank of Canada

(0.001%)

since

2025/06/30

18.

Bank of America Corp

(0.001%)

since

2025/06/30

19.

FMR Inc

(0.0004%)

since

2025/06/30

20.

Advisor Group Holdings, Inc.

(0.0004%)

since

2025/06/30

21.

Ground Swell Capital, LLC

(0%)

since

2025/06/30

22.

Sabby Management LLC

(0%)

since

2025/06/30

23.

Warberg Asset Management LLC

(0%)

since

2025/06/30

24.

Corsair Capital Management LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-5.8248

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(3.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.